"Wolverine stack" is one of the most searched peptide terms online, and almost none of the pages ranking for it explain what it actually is: a nickname, not a product. The name comes from the X-Men character's fictional rapid-healing ability, and internet shorthand attached it to a research combination of BPC-157 and TB-500, sometimes with KPV added. At TelosRX, we get asked about the "Wolverine stack" constantly, so this guide breaks down what each peptide is, what the preclinical research actually shows, and — critically — the current regulatory reality that anyone researching this combination needs to understand before assuming it's simply available for the asking.
What Does "Wolverine Stack" Actually Mean?
"Wolverine stack" is not an official pharmaceutical name, a branded product, or a formulation registered with any regulatory body. It's a piece of internet and gym-culture slang that grew out of biohacking and bodybuilding forums, referring loosely to a combination of two or three research peptides believed by some practitioners to support the body's own tissue-repair processes: BPC-157, TB-500 (thymosin beta-4), and occasionally KPV. The comic-book comparison is a marketing hook, not a scientific claim — there is no compound that replicates fictional accelerated healing, and no legitimate source should imply otherwise.
What's real is that each peptide in the stack has its own body of preclinical research, its own mechanism of action, and — this is the part most "Wolverine stack" content skips — its own distinct regulatory status. Understanding those individually is the only way to make sense of the combination.
BPC-157: Mechanism and Research Background
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a partial sequence identified in human gastric juice. It is not FDA-approved for any human use. It is studied in preclinical (largely animal and in-vitro) models for its potential role in tissue repair, and it is available in the United States only as a compounded preparation through a licensed pharmacy, dispensed under a valid prescription following evaluation by a licensed provider.
Preclinical research on BPC-157 has focused heavily on musculoskeletal soft tissue — tendons, ligaments, and muscle. A widely cited review describes how BPC-157 has been shown across multiple animal studies to accelerate healing of tendons, ligaments, muscle, and bone, with proposed mechanisms involving upregulation of growth hormone receptor expression in tendon fibroblasts, modulation of the VEGFR2 pathway, and support of nitric oxide signaling tied to angiogenesis (Sikiric et al., 2019, PubMed). A separate rat-model study specifically examined BPC-157's effect on disabled myotendinous junctions and reported improved functional recovery and tissue outgrowth compared to controls (Vukojević et al., 2021, PMC).
It's important to be precise about what this research does and doesn't show. These are animal and cell-culture studies, not large-scale human clinical trials. Human data on BPC-157 remains limited, and no specific efficacy percentage, healing timeline, or outcome should be assumed to translate directly from rodent models to human physiology. For a deeper walkthrough of BPC-157 on its own — history, proposed mechanisms, and what a compounded prescription pathway looks like — see TelosRX's BPC-157 patient guide.
TB-500 (Thymosin Beta-4): Mechanism and Research Background
TB-500 is the synthetic research name commonly associated with a fragment of thymosin beta-4 (Tβ4), a naturally occurring peptide found in nearly all mammalian cells that plays a role in actin regulation — the cytoskeletal protein involved in cell structure and movement. Preclinical work on thymosin beta-4 has looked at its involvement in wound healing and angiogenesis (new blood vessel formation). One frequently referenced study found that topical or systemic administration of Tβ4 increased wound re-epithelialization and collagen deposition in animal models compared to controls (Malinda et al., 1999, PubMed), and subsequent research identified the specific actin-binding domain of the peptide thought to drive its angiogenic activity.
As with BPC-157, this is preclinical and early-stage research — it maps a plausible biological mechanism, but it does not constitute proof of any specific outcome in humans, and no clinic can promise a particular result. TelosRX's dedicated TB-500 research article covers the mechanism and history in more depth.
Why the FDA's TB-500 Classification Matters Right Now
This is the single most important thing to understand about the "Wolverine stack" in 2026, and it's the reason a straight answer is hard to find: in late 2023, the FDA placed TB-500 (thymosin beta-4) on its bulk drug substances Category 2 list. Category 2 designates substances the FDA has identified as raising significant safety concerns or lacking sufficient evidence to support compounding for human use. Under this classification, licensed compounding pharmacies are currently prohibited from preparing or dispensing TB-500 for human administration.
In practical terms, that means any source currently offering to sell or compound "TB-500" for human use in the U.S. is doing so outside the boundaries that apply to legitimate, licensed compounding pharmacies — and TelosRX will not represent otherwise. This status is not permanent by definition; bulk drug substance classifications are periodically reviewed by the FDA and the Pharmacy Compounding Advisory Committee (PCAC), and availability is subject to how that regulatory picture evolves. But as of this writing, TB-500 is not something a compliant pharmacy can dispense, regardless of what "stack" it's marketed under.
This is also why framing the "Wolverine stack" as one purchasable bundle is misleading. BPC-157 and TB-500 currently sit in two different regulatory positions — one available by prescription through a licensed compounding pharmacy after provider evaluation, the other currently restricted at the compounding level entirely. Any responsible discussion of this topic has to separate the two rather than blur them into a single "stack" you can simply add to a cart.
Where KPV Fits In
Some versions of the "Wolverine stack" circulating online add a third peptide: KPV, a tripeptide (lysine-proline-valine) derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). KPV is studied in preclinical research for its anti-inflammatory signaling, largely independent of the classic melanocortin receptor pathway, with research suggesting it may inhibit NF-κB and MAP kinase inflammatory signaling and interact with the PepT1 transporter expressed in intestinal and immune cells (Lyons & Richards, 2003, PubMed).
The logic behind adding KPV to a tissue-repair-focused stack is that inflammation and repair are intertwined processes — some practitioners are interested in whether an anti-inflammatory peptide might complement peptides studied for structural tissue support. That is a research hypothesis, not an established clinical protocol, and there is no human trial data validating KPV as an adjunct specifically for tendon, ligament, or soft-tissue recovery. TelosRX covers KPV's inflammatory and gut-health research separately in more detail: see the KPV anti-inflammatory research article and the KPV gut health and IBD research article.
"Wolverine Stack" Components at a Glance
| Peptide | Structure | Primary Research Focus | Current U.S. Compounding Status |
|---|---|---|---|
| BPC-157 | 15-amino-acid pentadecapeptide | Tendon, ligament, muscle, and gut tissue repair (preclinical) | Available by prescription through licensed compounding pharmacies, subject to provider evaluation and ongoing PCAC review |
| TB-500 (Thymosin Beta-4) | Fragment of a 43-amino-acid peptide | Angiogenesis, wound re-epithelialization, actin regulation (preclinical) | FDA Category 2 bulk substance — currently prohibited from compounding for human use |
| KPV | 3-amino-acid tripeptide (α-MSH fragment) | Anti-inflammatory signaling, gut barrier research (preclinical) | Availability subject to individual provider evaluation and evolving PCAC/FDA status |
Research Ranges Discussed in the Literature (Not a Prescriptive Protocol)
The ranges below reflect what has been described in preclinical studies and secondary research literature — they are provided for educational context only, are not a treatment protocol, and are not a recommendation to self-administer anything. Any decision about whether a compounded peptide is appropriate, and at what dose, frequency, or duration, is made exclusively by a licensed provider after individual evaluation, and only for substances a licensed pharmacy can currently and lawfully compound.
| Peptide | Ranges Discussed in Literature/Provider Context | Typical Research Duration | Notes |
|---|---|---|---|
| BPC-157 | Microgram-range dosing has been discussed in provider and research contexts, administered subcutaneously | Several weeks in most cited protocols | Not a prescriptive protocol; determined solely by an evaluating provider |
| TB-500 | Not applicable | Not applicable | Currently unavailable for compounding under FDA Category 2 status |
| KPV | Low-microgram-range dosing has been discussed in some provider protocols | Varies by individual evaluation | Not a prescriptive protocol; subject to PCAC review and provider discretion |
Safety and Regulatory Reality Check
Before considering any peptide discussed in this article, it's worth being direct about where things actually stand:
- FDA approval status: Neither BPC-157 nor TB-500 nor KPV is FDA-approved for any human therapeutic use. Where a compliant compounding pathway exists (currently BPC-157 and KPV, subject to provider evaluation), it operates under federal and state compounding regulations — it is not the same as an FDA-approved drug, and approval by a provider for an individual patient is never automatic or guaranteed.
- TB-500's Category 2 status: As detailed above, TB-500 was placed on the FDA's Category 2 bulk drug substances list in late 2023, which currently prohibits licensed compounding pharmacies from preparing or dispensing it for human use. This status is subject to change as FDA and PCAC review continues, but it is the operative reality today.
- Competitive athletes — WADA/USADA status: BPC-157 is explicitly named in WADA's Prohibited List under the S0 "Non-Approved Substances" category, which covers any pharmacological substance without current approval by a governmental health authority for human therapeutic use. This category is prohibited at all times, in and out of competition, with no therapeutic use exemption available. Peptides such as TB-500 and KPV fall under the same S0 catch-all logic. Any athlete subject to WADA, USADA, or a similar testing body should treat all three peptides in this article as prohibited substances and consult their sport's anti-doping authority directly — this article is not sports-eligibility guidance.
- Individual evaluation required: Nothing in this article is a recommendation to use any specific peptide. Whether a compounded preparation is appropriate for a given patient — and whether it can currently be lawfully compounded at all — is a determination made by a licensed provider on a case-by-case basis.
If you're researching the BPC-157 side of this combination and want to talk to a licensed provider about whether an evaluation makes sense for you, TelosRX's BPC-157 + TB-500 research page outlines the current program and evaluation process. Start your private evaluation at TelosRX to see what's currently available and appropriate for your situation — availability of any individual peptide remains subject to provider judgment and current regulatory status, including the TB-500 restriction described above.
Frequently Asked Questions
Is the "Wolverine stack" a real medical product?
No. "Wolverine stack" is an informal nickname that spread through online fitness and biohacking communities, not an approved drug, a branded formulation, or a term recognized by any regulatory body. It refers loosely to combining BPC-157 and TB-500, sometimes with KPV, based on their individual research profiles.
Can I currently get TB-500 from a compounding pharmacy?
No, not for human use. The FDA classified TB-500 as a Category 2 bulk drug substance in late 2023, which currently prohibits licensed compounding pharmacies from preparing or dispensing it for human administration. This is a regulatory restriction, not a supply issue, and it applies regardless of which pharmacy or telehealth provider is asked.
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved for any human use. Where available, it is dispensed as a compounded preparation by a licensed pharmacy under valid prescription, following evaluation by a licensed provider, and is prepared under federal and state compounding regulations rather than as an approved drug.
Are BPC-157 and TB-500 banned for athletes?
BPC-157 is explicitly named under WADA's S0 "Non-Approved Substances" category, prohibited at all times with no therapeutic use exemption. TB-500 and KPV fall under the same S0 category as unapproved research peptides. Any competitive athlete subject to WADA, USADA, or a similar body should assume all three are prohibited and confirm directly with their sport's anti-doping authority.
What does KPV add to the stack, and is it necessary?
KPV is studied in preclinical research for anti-inflammatory signaling, distinct from the tissue-repair mechanisms studied for BPC-157 and TB-500. Some practitioners are interested in whether it might complement a repair-focused protocol, but there is no clinical trial establishing KPV as a necessary or proven adjunct — it is a separate peptide with its own research base, not a required component.
Does preclinical research guarantee these peptides will work for me?
No. Preclinical research — animal studies and cell-culture models — can suggest a biological mechanism worth studying further, but it does not prove a specific outcome in humans. Human clinical trial data for BPC-157, TB-500, and KPV remains limited, and no clinic can promise or imply a guaranteed result.
How do I find out if any of this is currently appropriate for me?
Talk to a licensed provider. TelosRX's evaluation process reviews your individual history before determining what — if anything — is currently appropriate and lawfully available to compound. You can start that process on the BPC-157 + TB-500 page.
Want a licensed provider to review which of these peptides is currently available and appropriate for you? Start a private online visit.
TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.
Curious whether the BPC-157 side of this research is right for you? Start your private evaluation at TelosRX today.